Archive: April 2017

The Best Treatments to Use After Checkpoint Inhibition in Melanoma

Grant McArthur, MBBS, PhD

H&O  Which patients with melanoma are candidates for checkpoint inhibition? GM  All patients with unresectable metastatic melanoma—stage IV and unresectable stage III disease—are candidates for checkpoint […]

Antibody-Drug Conjugates in Breast Cancer

Aditya Bardia, MD, MPH

  H&O  What are antibody-drug conjugates (ADCs)? AB  ADCs are drugs that contain an antibody linked to a chemotherapy agent. Accordingly, they have 3 components: an antibody […]

Treatment of Acute Lymphoblastic Leukemia in Older Adults: Now and the Future

Musa Yilmaz, MD, Hagop Kantarjian, MD, and Elias Jabbour, MD

  Abstract: Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, […]

Myeloma Bone Disease: Pathogenesis and Treatment

Elizabeth K. O’Donnell, MD, and Noopur S. Raje, MD

  Abstract: Bone involvement manifesting as osteolytic bone disease (OBD) or osteopenia is one of the defining features of multiple myeloma (MM). Osteolytic lesions develop in […]

Advances in the Management of Patients With Carcinoid Syndrome

Matthew H. Kulke, MD

  H&O  What are the symptoms of carcinoid syndrome? MK  Carcinoid syndrome can occur in patients who have carcinoid tumors. Carcinoid tumors have the ability to […]

What Should Frontline Treatment Be in Chronic Myeloid Leukemia?

Stephanie Glancy Lee, MD, FRCPC, Jeffrey H. Lipton, PhD, MD, FRCPC, Carmen Fava, MD, PhD, and Giuseppe Saglio, MD

The US Food and Drug Administration has approved 3 tyrosine kinase inhibitors (TKIs) for use as frontline treatment in chronic myeloid leukemia (CML): imatinib, dasatinib (Sprycel, […]

How Direct-to-Patient Research Can Improve Interest in Clinical Trials

Deborah Collyar

  H&O  What are the challenges involved in patient recruitment and retention in traditional clinical trials? DC  There are so many challenges. For example, most traditional […]

The Use of CAR T Cells in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

Peter Martin, MD, MS

  H&O  Why are new treatments needed in DLBCL and MCL? PM  Existing therapies are ineffective in a subset of patients or have toxicities that make […]

Genetic Conditions Associated With a Predisposition to Kidney Cancer

  Based on a presentation by W. Marston Linehan, MD, at the ASCO Genitourinary Cancers Symposium  Scientists have identified at least 13 genes that pre­dispose patients […]

News

Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4 By Devon Schuyler Pembrolizumab Improves Survival in Advanced Urothelial Cancer Pembrolizumab (Keytruda, Merck) improved […]

Letter from the Editor: Affordable Care?

Brad S. Kahl, MD

Nobody knew health care could be so complicated. – President Donald Trump Actually, lots of people did. In the president’s defense, I am sure he never […]

Back to Archive